Total Live Articles: 383

Cervical Ectropion

No dedicated stand-alone NICE CKS or major international treatment guideline was identified for cervical ectropion.

Therefore, this article is primarily based on the StatPearls review by Aggarwal and Ben Amor.

Cervical Ectropion

Cervical ectropion is a benign gynaecological finding characterised by the presence of glandular columnar epithelium on the ectocervix, where it is normally covered by non-glandular stratified squamous epithelium.

This updated UKMLA guide to cervical ectropion covers causes and risk factors, symptoms, diagnosis and management of cervical ectropion.

Histology

Normal cervical histology:

Region Normal epithelium
Endocervix (endocervical canal) Glandular columnar epithelium
Ectocervix Non-keratinised stratified squamous epithelium

In cervical ectropion:

  • Glandular columnar epithelium (normally lines the endocervix), becomes visible on the ectocervix (which is normally squamous)

Causes and Risk Factors

Cervical ectropion is strongly related to increased oestrogen levels (oestrogen causes the proliferation and differentiation of cervical epithelium)

Risk factors are those associated with high oestrogen exposure:

  • During years of menstruation (uncommon in post-menopausal women due to the declining oestrogen levels)
  • Pregnancy
  • Hormonal contraception use

Clinical Features

Cervical ectropion is most commonly asymptomatic.

If symptomatic:

  • Vaginal discharge (non-purulent, white or yellow) – most common symptom
  • Post-coital bleeding – classic but only seen in 5-25% cases
  • Intermenstrual bleeding
  • Dyspareunia

Red Flags and Referral Criteria

If a >55 y/o woman presents with unexplained post-menopausal bleeding → suspected endometrial cancer pathway referral

See the Endometrial Cancer article for more information.

Investigation and Diagnosis

Since cervical ectropion is most commonly asymptomatic, most cases are diagnosed incidentally during a pelvic examination or during cervical screening (Pap smear).

Cervical ectropion is usually a clinical diagnosis made on speculum examination:

  • Direct visualisation of a red, ring-like area surrounding the external cervical os (the exposed columnar epithelium on the ectocervix)
  • Cervical ectropion may be associated with contact bleeding as the exposed column epithelium is relatively fragile

Other investigations to exclude other causes:

  • If there is purulent vaginal discharge → vaginal swabs
  • NAAT to test for chlamydia and gonorrhoea
  • If CIN cannot be ruled out on macroscopic visualisation → consider pap smear, colposcopy, biopsy

Management

Cervical ectropion is benign and does NOT require routine treatment.

Only consider treatment if symptoms are affecting the patient’s quality of life:

  • 1st line: discontinue any hormonal contraceptives
  • Interventional treatment options
    • Cautery (electrocautery or cryotherapy)
    • Microwave tissue coagulation
    • Laser therapy

References

Related Articles

Cervical Intraepithelial Neoplasia (CIN)

Cervical Cancer

Contraception (Non-Emergency)

Endometrial Cancer

Share Your Feedback Below

Disclaimer

We’re actively expanding Guideline Genius to cover the full UKMLA content map. Therefore, you may notice some conditions not uploaded yet, or articles that currently focus on diagnosis and management for now.

We are also continuously reviewing and updating existing content to ensure accuracy and alignment with current guidelines. Some earlier articles are undergoing revision as part of this process. Once all content has been fully reviewed, this will be clearly communicated on the platform.

For updates, follow us on Instagram @guidelinegenius.

We welcome any feedback or suggestions via the anonymous feedback box at the bottom of each article and will do our best to respond promptly.

Thank you for your support.
The Guideline Genius Team

UK medical guidelines made easy. From guidelines to genius in minutes!

Quick Links

Cookie Policy

Social Media

© 2026 GUIDELINE GENIUS LTD

Be first to accessour QBank

Sign up to receive major guideline updates and early access when we launch.